Banerji, Udai

Combinatorial drug therapy for cancer in the post-genomic era

Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 1,070

Combine and conquer: challenges for targeted therapy combinations in early phase trials

Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology

Lung Cancer Treatments and MutationsStatistical Methods in Clinical Trials

Cited by 394

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

Wagner, A. J., Banerji, U., Mahipal, A., Somaiah, N., Hirsch, H., Fancourt, C., Johnson-Levonas, A. O., Lam, R., Meister, A. K., Russo, G., et al. (2017) · Journal of Clinical Oncology

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 120

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., et al. (2020) · The Lancet Oncology

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 78

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., et al. (2021) · Annals of Oncology

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 21

725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

Banerjee, S., Grochot, R., Shinde, R., Lima, J., Krebs, M., Rahman, R., Little, M., Tunariu, N., Curcean, A., Badham, H., et al. (2021) · Annals of Oncology

Ovarian cancer diagnosis and treatmentOvarian function and disorders

Cited by 17

Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

Krebs, M. G., Shinde, R., Rahman, R. A., Grochot, R., Little, M., King, J., Kitchin, J., Parmar, M., Turner, A., Mahmud, M., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 10

Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response

Stewart, A. R., Pickard, L., Paranjape, E., Perez, V. S., Chowdhury, S., Lustgarten, S., Coma, S., Pachter, J. A., Carey, M. S., DiMattia, G., et al. (2022) · Cancer Research

Ovarian cancer diagnosis and treatmentMelanoma and MAPK Pathways

Cited by 1